0.05Open0.05Pre Close0 Volume91 Open Interest10.00Strike Price0.00Turnover337.73%IV407.58%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier25DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.0849Delta0.0883Gamma39.60Leverage Ratio-0.0053Theta0.0001Rho3.36Eff Leverage0.0008Vega
Amylyx Pharmaceuticals Stock Discussion
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) has recently announced the acquisition of avexitide from Eiger BioPharmaceuticals, Inc. Avexitide has already garnered considerable attention for its potential therapeutic benefits and has received designations from the U.S. Food and Drug Administration (FDA). This article delve...
Dow Jones· 11 mins ago! Is to enter Phase 3 Trial in Q1 2025!
No comment yet